Syquant Capital Sas 89bio, Inc. Transaction History
Syquant Capital Sas
- $348 Million
- Q3 2025
A detailed history of Syquant Capital Sas transactions in 89bio, Inc. stock. As of the latest transaction made, Syquant Capital Sas holds 2,593,694 shares of ETNB stock, worth $38.5 Million. This represents 10.94% of its overall portfolio holdings.
Number of Shares
2,593,694Holding current value
$38.5 Million% of portfolio
10.94%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
210Shares Held
161MCall Options Held
299KPut Options Held
1.61M-
Janus Henderson Group PLC London, X020.8MShares$308 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million4.27% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.2MShares$211 Million4.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.5MShares$141 Million3.31% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.24MShares$122 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...